购物车
您的购物车当前为空
ABBV-706是一种抗体-药物偶联物(ADC),靶向受体酪氨酸激酶SEZ6,在肿瘤细胞表面结合后可内吞并释放细胞毒载荷,从而诱导肿瘤细胞死亡。ABBV-706目前处于临床研究阶段,在小细胞肺癌等实体瘤中显示出潜在的抗肿瘤活性。
ABBV-706是一种抗体-药物偶联物(ADC),靶向受体酪氨酸激酶SEZ6,在肿瘤细胞表面结合后可内吞并释放细胞毒载荷,从而诱导肿瘤细胞死亡。ABBV-706目前处于临床研究阶段,在小细胞肺癌等实体瘤中显示出潜在的抗肿瘤活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 8,250 | 6-8周 | |
| 5 mg | ¥ 18,200 | 6-8周 | |
| 10 mg | ¥ 27,300 | 6-8周 | |
| 50 mg | 待询 | 6-8周 |
| 产品描述 | ABBV-706 is an antibody-drug conjugate (ADC) that targets the receptor tyrosine kinase SEZ6. After binding to the surface of tumor cells, it is internalized and releases a cytotoxic payload, thereby inducing tumor cell death. ABBV-706 is currently in clinical development and has demonstrated potential antitumor activity in solid tumors such as small cell lung cancer. |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 存储 |
对于不同动物的给药剂量换算,您也可以参考 更多